Cardio Diagnostics Holdings (NASDAQ: CDIO) announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD and PrecisionCHD tests for eligible members with prior authorization. This expansion is expected to increase adoption of precision cardiovascular medicine within community healthcare networks.
The Epi+Gen CHD test evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD helps diagnose coronary heart disease and identify its underlying molecular drivers. Both tests are noninvasive blood-based diagnostics that do not require fasting or radiation exposure, potentially lowering barriers to early detection and personalized treatment planning.
By integrating these tests into Atlas Healthcare Physicians’ network, Cardio Diagnostics aims to bring advanced cardiovascular risk assessment to a broader patient population. The company emphasizes that its tests leverage an AI-driven Integrated Genetic-Epigenetic Engine to provide more precise insights compared to traditional methods.
This development is significant as coronary heart disease remains a leading cause of death in the United States. Access to noninvasive, blood-based diagnostics could help clinicians identify high-risk patients earlier and tailor interventions more effectively, potentially reducing the burden of cardiovascular events.
For more details, the full press release is available at https://nnw.fm/EFQen. Additional information about Cardio Diagnostics and its latest updates can be found in the company’s newsroom at https://ibn.fm/CDIO.
